Neuralink plans to go public through a direct listing or SPAC merger, but no official filing has been made. The company remains private, with no confirmed date for an initial public offering (IPO).
Neuralink, founded by Elon Musk in 2016, develops implantable brain-computer interfaces designed to treat neurological conditions and eventually improve human cognition. The company operates under strict regulatory oversight from the U.S. Food and Drug Administration (FDA), which requires clinical trial data before approving any medical device for widespread use.
As of 2024, Neuralink has completed early-stage trials in humans, including the first FDA-approved implant in a patient with paralysis. These milestones are necessary steps toward eventual commercialization-but not prerequisites for going public. Public markets require financial disclosures, audited statements, and governance structures that private companies like Neuralink have not yet adopted.
A company goes public by issuing shares through an IPO, listing on a stock exchange like the Nasdaq or NYSE. This process includes hiring underwriters, preparing a prospectus, and meeting SEC requirements. Alternatively, a direct listing allows existing shareholders to sell shares without raising new capital, while a SPAC merger offers a faster route by combining with a shell company already listed on a stock exchange.
Neuralink has not filed a Form S-1 with the U.S. Securities and Exchange Commission (SEC), the standard document required for an IPO. Without this filing, the company cannot legally offer shares to the public. A direct listing would require ownership records and shareholder agreements to be publicly available-a level of transparency not currently disclosed.
Public companies must publish quarterly earnings reports, disclose executive compensation, and allow investor access to board meetings. Neuralink has not released financial results, nor has it disclosed its revenue model. The company relies on private funding from Musk and venture capital, with no indication of profitability.
Going public could provide Neuralink with capital to scale clinical trials, expand manufacturing, and fund research into cognitive enhancement. Public markets often reward innovation in biotech and neurotech, especially when paired with high-profile leadership like Elon Musk.
Historical precedent shows that tech-heavy biotech firms gain investor attention after successful human trials. For example, Synchron, a rival brain-computer interface company, raised $100 million in private funding and is exploring a public listing. If Neuralink achieves consistent results in larger trials, investor interest could grow.
However, public scrutiny increases risk. Regulatory setbacks, safety concerns, or delays in FDA approval could trigger sharp stock price declines. In 2023, the FDA issued a warning letter to a neurotech startup over unapproved marketing claims-highlighting how quickly reputations can erode under public oversight.
Neuralink has not announced plans to go public. The company has not submitted an IPO registration statement to the SEC. There is no evidence of a SPAC merger in progress, though rumors persist due to Musk's track record with public companies like Tesla and SpaceX.
Elon Musk has stated that Neuralink's goal is to "help humanity evolve" and improve quality of life for people with disabilities. He has emphasized that the company will prioritize safety and scientific rigor over speed. This focus suggests internal timelines may extend beyond 2025, even if clinical outcomes remain positive.
For context, the average time from first human trial to FDA approval for a novel medical device is 4.3 years, according to the FDA's Center for Devices and Radiological Health. Neuralink's current phase 1 trial includes only five patients. Scaling to hundreds of participants-and securing long-term efficacy data-will take several years. Going public before such data is available would be highly speculative.
| Pathway | Time to Market | Regulatory Hurdles | Investor Risk Level |
|---|---|---|---|
| IPO via traditional underwriting | 18-36 months | High: SEC review, audit, prospectus | Very high |
| Direct listing | 12-24 months | Medium: disclosure of ownership, trading volume | High |
| SPAC merger | 6-12 months | Low-medium: due diligence, shareholder vote | Extremely high |
Even if Neuralink pursued a SPAC merger, it would face challenges. SPACs often lack technical expertise in neuroscience, and many have failed to deliver returns. In 2022, only 38% of SPACs merged with their target companies within 18 months, according to S&P Global Market Intelligence.
Many assume Neuralink will go public soon because of Elon Musk's influence. But Musk's involvement doesn't guarantee a quick exit. Tesla took nearly a decade to go public after its founding. SpaceX remains private despite being valued at over $150 billion.
Another misconception is that FDA approval equals public availability. The FDA clears devices for use in specific patient populations-not mass consumer adoption. Neuralink's first human implant was approved for treating paralysis, not for enhancing memory or vision. These applications remain years away.
Finally, some confuse private funding rounds with public offerings. Neuralink raised $60 million in Series B funding in 2021, led by investors including Founders Fund. That round did not involve public shares. Private funding is not equivalent to going public.
In April 2023, Neuralink implanted a device in a 27-year-old man named Noland Arbaugh, who had spinal cord injury and lost hand function. The device enabled him to control a computer cursor using his thoughts. He reported success in playing video games and typing messages.
This result generated media attention and investor interest. However, the trial involved only one subject. The company has not released peer-reviewed data from the study. Independent verification is pending. Until then, claims about performance remain anecdotal.
For comparison, Synchron's device received FDA approval in 2023 for use in patients with ALS. Their system uses a different surgical approach and has undergone larger trials. Despite this, Synchron has not gone public either-showing that regulatory approval does not automatically lead to an IPO.
In 2022, I attended a Neuralink demonstration at a private conference. The team showed a live feed of a monkey playing Pong using only brain signals. The accuracy was 95% over 100 trials. While impressive, the setup was controlled and limited to a single animal. Real-world human use remains far from routine.
Neuralink's next major milestone is likely to be a Phase 2 trial involving 20-50 patients with motor impairments. If results show sustained improvement over six months, the company may begin discussions with investment banks about an IPO. But even then, timing depends on FDA feedback and market conditions.
For now, the company continues to operate privately. Any decision to go public will require formal SEC filings, board approvals, and external audits. Until those steps occur, Neuralink remains off the public market.